A Multicenter, Prospective, Non-interventional Study of Maintenance Avastin® (Bevacizumab) Following Induction Treatment With Platinum Doublet Plus Avastin® in Patients With Advanced Lung Adenocarcinoma
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Bevacizumab (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- Sponsors Roche
- 01 Dec 2017 Planned End Date changed from 31 Oct 2017 to 10 Feb 2018.
- 01 Dec 2017 Planned primary completion date changed from 31 Oct 2017 to 10 Feb 2018.
- 02 Oct 2017 Status changed from recruiting to active, no longer recruiting.